Showing 5291-5300 of 6036 results for "".
- In-Person ESCRS and Euretina Meetings Cancelled; Virtual Meetings Plannedhttps://modernod.com/news/escrs-and-euretina-meetings-cancelled-virtual-meetings-planned/2477843/Due to the COVID-19 pandemic, the in-person ESCRS and Euretina meetings, scheduled to take place in Amsterdam in October, have been cancelled. Instead, the 38th Congress of the ESCRS and the 20th Euretina Congress will be held in a virtual format. In a joint letter to their memberships, ES
- A New Law in Laser Physics Could Make Eye Surgery Simplerhttps://modernod.com/news/a-new-law-in-laser-physics-could-make-eye-surgery-simpler/2477830/Scientists have developed a new type of laser that can deliver high amounts of energy in very short bursts of time, with potential applications in eye and heart surgery or the engineering of delicate materials, according to a
- U.S. Lawmakers Unveil Bold $100 Billion Plan to Remake NSFhttps://modernod.com/news/u-s-lawmakers-unveil-bold-100-billion-plan-to-remake-nsf/2477829/The National Science Foundation (NSF) would get a sweeping remake—including a new name, a huge infusion of cash, and responsibility for maintaining U.S. global leadership in innovation—under bipartisan bills that have just been introduced in both houses of Congress, according to a
- Caren Mason, CEO of Starr Surgical, Named to Top 50 Healthcare Technology CEOs Of 2020https://modernod.com/news/caren-mason-ceo-of-starr-surgical-named-to-top-50-healthcare-technology-ceos-of-2020/2477827/The Healthcare Technology Report announced The Top 50 Healthcare Technology CEOs of 2020. Data on each CEO’s professional background was gathered and they were assessed across several key areas, including breadth of leadership experience in the healthcare technology industry, level of exper
- InMed Releases CBN Preclinical Results in Glaucomahttps://modernod.com/news/inmed-releases-cbn-preclinical-results-in-glaucoma/2477826/InMed Pharmaceuticals provided an update on the preclinical results from its INM-088 drug development program that indicate a potential neuroprotective effect of cannabinol (CBN) on nerve cells located in the eye. INM-088 is being developed as a potential treatment option for ocular diseases, suc
- Bausch + Lomb Announces European Launch of a New Platform of Preloaded IOLs, LuxSmart and LuxGoodhttps://modernod.com/news/bausch-lomb-announces-the-launch-of-a-new-platform-of-preloaded-iols-luxsmart-and-luxgood/2477823/Bausch + Lomb announced the European launch of the company’s first presbyopia correcting IOL, LuxSmart, and its monofocal version, LuxGood. Both feature preloaded delivery systems and Pure Refractive Optics (PRO) Technology. LuxSmart and LuxGood comprise a hydrophobic material and repres
- Genentech: Longer-Term Data Reinforce Safety of Satralizumab in Adults and Adolescents With NMOSDhttps://modernod.com/news/genentech-longer-term-data-reinforce-safety-of-satralizumab-in-adults-and-adolescents-with-nmosd/2477813/Genentech will present new pooled pivotal satralizumab safety results for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating central nervous system disorder. These data are being presented at the 6th annual meeting of the European Academy of Neurology (EAN) and
- Mayo Clinic, CommonSpirit, and Mass General Feel Hit From COVID-19 in Q1https://modernod.com/news/mayo-clinic-commonspirit-and-mass-general-feel-hit-from-covid-19-in-q1/2477795/Major health systems the Mayo Clinic, CommonSpirit Health, and Mass General Brigham revealed the first details on how the COVID-19 pandemic is hitting them financially, with some systems reporting millions in losses, according to a FierceHealthcare
- Market Scope: Premium IOLs Expected to Drive Market Growth Over the Next 5 Yearshttps://modernod.com/news/market-scope-premium-iols-expected-to-drive-market-growth-over-the-next-5-years/2477796/The revenue contribution of premium IOLs is expected to grow over the next 5 years as the number and different types of IOL designs offered to cataract and refractive patients seeking better visual outcomes increases, according to a Market Scope report. In 2019, premium IOLs accounted a th
- Atia Vision Closes Second Tranche Of $20M In Series D Financinghttps://modernod.com/news/atia-vision-closes-second-tranche-of-20m-in-series-d-financing/2477793/Atia Vision, which is developing of a modular presbyopia-correcting accommodating IOL, announced the closing of its second tranche of a Series D $20M financing. The financing will be used to continue early clinical experience treating cataract patients and support ex